Amit Chunilal Nathwani
Fondatore presso Freeline Therapeutics Ltd.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Chris Hollowood | M | 50 |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | 9 anni |
Michael Parini | M | 49 | 3 anni | |
Colin Love | M | 65 |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | 3 anni |
Markus Hörer | M | - | 9 anni | |
Paul Schneider | M | 54 | 2 anni | |
Mark Lowdell | M | 61 |
Royal Free Hospital Medical School
University College London
| 30 anni |
Sarah Whitney | F | 60 |
University College London
| - |
James Bircher | M | 56 | 3 anni | |
Nilesh Modi | M | 55 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Brian Silver | M | 55 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 4 anni |
Mark P. Richmond | M | 92 |
University College London
| - |
Pamela Foulds | M | 55 | 3 anni | |
Simon Aron Goldman | M | 45 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Saladin Meckled-Garcia | M | - |
University College London
| - |
Martin Andrews | M | 61 |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | - |
Seung Suh Hong | M | 66 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 3 anni |
Katharine Roseveare | F | - |
University College London
| - |
Christopher Mason | M | 66 |
University College London
| 25 anni |
Scott Clarke | M | - |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 1 anni |
Bharat Kumar Hirji Thakrar | M | 67 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Julia Prescot | F | 65 |
University College London
| - |
Ven Balakrishnan | M | - |
University College London
| - |
Stephanie Schorge | M | - |
University College London
| - |
David Attwell | M | - |
University College London
| - |
Magnus Nyden | M | - |
University College London
| - |
Arne Naeveke | M | - | 2 anni | |
Amy J. Spandau | F | - | 2 anni | |
Henning R. Stennicke | M | 57 | 2 anni | |
Melissa Terras | F | - |
University College London
| - |
Claire Callender | F | - |
University College London
| - |
Mark Miodownik | M | - |
University College London
| - |
Wendy Appleby | F | - |
University College London
| - |
Maria Wyke | F | - |
University College London
| - |
Peter Cadley | M | - |
University College London
| - |
Paul Ayris | M | - |
University College London
| - |
Nigel Waugh | M | - |
University College London
| - |
Clare Goudy | F | - |
University College London
| - |
Mark Sudbury | M | - |
University College London
| - |
Nick McGhee | M | - |
University College London
| - |
Mariana Mazzucato | M | 56 |
University College London
| 7 anni |
Sergio Quezada | M | 49 |
University College London
| 13 anni |
Samit Govindji Hathi | M | 57 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Stanton Peter Newman | M | 75 |
University College London
| - |
William Rosenberg | M | - |
University College London
| - |
Derek Lionel Glendon Hill | M | 58 |
University College London
| 29 anni |
Adele Biss | F | - |
University College London
| - |
David Knox | M | 66 |
University College London
| - |
John Marshall | M | 80 |
University College London
| - |
John Reid | M | 77 |
University College London
| - |
Peter Parker | M | - |
University College London
| - |
Ted Dinan | M | - |
University College London
| - |
Michael Pepper | M | - |
University College London
| 15 anni |
José-Alain Sahel | M | 68 |
University College London
| - |
Roy Quilliam | M | 63 |
University College London
| - |
Vanessa Lawrence | M | - |
University College London
| - |
Mark Emberton | M | - |
University College London
| - |
DeAnne Shirley Julius | M | 75 |
University College London
| 10 anni |
John Collinge | M | 66 |
University College London
| - |
John W. Martin | M | - |
University College London
| - |
Josephine Clare Baroness Valentine | F | 66 |
University College London
| - |
Dame Angela Strank | M | 71 |
University College London
| - |
Julia Gregory | F | 71 |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | - |
Richard Fagan | M | 63 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Shervanthi Homer-Vanniasinkam | M | 65 |
University College London
| - |
Ian Dato | M | 46 |
University College London
| - |
Kai Kit Wong | M | 50 |
University College London
| 9 anni |
Jeffrey Chodakewitz | M | 68 |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | - |
Junaid Bajwa | M | 45 |
University College London
| - |
Matt Harvey | M | - |
University College London
| - |
Chris Russell | M | - |
University College London
| - |
Dominic Blakemore | M | 54 |
University College London
| - |
Derralynn Hughes | F | - |
University College London
| - |
Michael Arthur | M | - |
University College London
| 11 anni |
Michael Owen | M | 73 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 1 anni |
Quentin Pankhurst | M | - |
University College London
| - |
David Delpy | M | - |
University College London
| 25 anni |
Nicole Jones | F | 54 | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Anne Prener | M | 66 |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | 2 anni |
Theresa Heggie | F | 63 | 1 anni | |
Lina Sio | F | 29 |
University College London
| 5 anni |
Rory McGee | M | - |
University College London
| 5 anni |
Ragav Manimaran | M | - |
University College London
| 6 anni |
Benjamin Warriner | M | - | 5 anni | |
Stephen P. Diamond | M | - | 1 anni | |
Sri Ayangar | M | - |
University College London
| 4 anni |
Jia Qiao Zhao | F | 28 |
University College London
| 6 anni |
Jan Thirkettle | M | - |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | - |
Tanel Ozdemir | M | - |
University College London
| 5 anni |
Lujie Chen | M | - |
University College London
| 3 anni |
Konstantin Synetos | M | - |
University College London
| 3 anni |
Qian Wu | M | 35 |
University College London
| 1 anni |
Hana Besbes | F | - |
University College London
| 1 anni |
Marta Pyrzyk | F | - |
University College London
| 1 anni |
Chen Yan Xu | M | 34 |
University College London
| 1 anni |
Aisha Hamid | F | 32 |
University College London
| 3 anni |
Miia Bovellan | F | - |
University College London
| 4 anni |
Ka Fung Hon | M | 34 |
University College London
| 4 anni |
Swathi Nair | F | - |
University College London
| 3 anni |
Alexander Mann | M | - |
University College London
| 3 anni |
Tim Safin | M | - |
University College London
| 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Amit Chunilal Nathwani
- Contatti personali